Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 6:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 307 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Heart Diseases in Pregnancy Clear all
Terminated Phase 2 Interventional Results available

A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure

NCT03152552
View directory record Official record
Conditions
Diabetes Mellitus and Heart Failure
Interventions
LIK066, Placebo, Empagliflozin
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
21
States / cities
Huntsville, Alabama • Carmichael, California • Concord, California + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 6, 2026, 6:06 AM EDT
Completed Not applicable Interventional

Optimizing In-hospital Use of Evidence-based Therapies for Patients With Cardio-Renal-Metabolic Disease

NCT05781334
View directory record Official record
Conditions
Heart Failure, Type 2 Diabetes, Chronic Kidney Diseases
Interventions
Virtual Consult Intervention
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 20, 2024 · Synced Oct 6, 2026, 6:06 AM EDT
Active, not recruiting Not applicable Interventional

Mobile Health Interventions to Prevent Heart Disease After Hypertensive Disorders of Pregnancy

NCT06523569
View directory record Official record
Conditions
Hypertension in Pregnancy, Pre-Eclampsia, Eclampsia, Gestational Hypertension
Interventions
Digital Blood Pressure Monitoring System, Mobile health application
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 6, 2026, 6:06 AM EDT
Completed No phase listed Observational

"Treatment Use of ECMO In Pregnancy or Peripartum Patient."

NCT04144660
View directory record Official record
Conditions
Cardiogenic Shock, Peripartum Cardiomyopathy, Complication, Pregnancy
Interventions
Extracorporeal Membrane Oxygenation
Device
Lead sponsor
Sarah Thordsen
Other
Eligibility
18 Years and older · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Oct 6, 2026, 6:06 AM EDT
Completed Not applicable Interventional Results available

Look AHEAD: Action for Health in Diabetes

NCT00017953
View directory record Official record
Conditions
Diabetes, Myocardial Infarction, Stroke, Kidney Diseases, Bone Diseases, Dyslipidemia
Interventions
Lifestyle Intervention, Diabetes Support and Education
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
55 Years to 76 Years
Enrollment
5,145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2020
U.S. locations
18
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2023 · Synced Oct 6, 2026, 6:06 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Do Elevated BNP Levels Predict Hemodynamically Significant PDAs

NCT01497054
View directory record Official record
Conditions
Patent Ductus Arteriosus
Interventions
Not listed
Lead sponsor
Albany Medical College
Other
Eligibility
1 Hour to 24 Hours
Enrollment
109 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Jul 4, 2013 · Synced Oct 6, 2026, 6:06 AM EDT
Completed No phase listed Observational

Monitoring of Vital Signs During Skin-to-skin Holding by Mothers of Their Preterm Babies

NCT02231801
View directory record Official record
Conditions
Other Preterm Infants
Interventions
Mother-Infant Dyad
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
30 Weeks to 35 Weeks
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 31, 2015 · Synced Oct 6, 2026, 6:06 AM EDT
Terminated Phase 2 Interventional

Safety, Tolerability and Pharmacodynamics of AP214 Acetate in Patients Undergoing Cardiac Surgery

NCT00628264
View directory record Official record
Conditions
Cardiac Surgery, Coronary Artery Bypass Grafting, Valve Surgery, Kidney Injury
Interventions
AP214, Placebo
Drug
Lead sponsor
Action Pharma A/S
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 1, 2009 · Synced Oct 6, 2026, 6:06 AM EDT
Completed Phase 2 Interventional

Effect of Extended Release Torsemide in Patients With Congestive Heart Failure and Overactive Bladder

NCT06206512
View directory record Official record
Conditions
Heart Failure, Overactive Bladder, Incontinence
Interventions
Extended release torsemide, Immediate release torsemide, Extended release torsemide placebo, Immediate release torsemide placebo
Drug
Lead sponsor
Sarfez Pharmaceuticals, Inc.
Industry
Eligibility
50 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 6, 2026, 6:06 AM EDT
Completed Phase 1Phase 2 Interventional

BNP (Nesiritide) vs. Placebo to Protect Kidney Function in Patients Undergoing Heart Bypass Surgery.

NCT00252200
View directory record Official record
Conditions
Acute Kidney Failure
Interventions
Neseritide
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 23, 2009 · Synced Oct 6, 2026, 6:06 AM EDT
Withdrawn No phase listed Observational

A Zero Acute Kidney Injury Strategy for Percutaneous Coronary Intervention in Patients With ChronicKidney Disease

NCT04928092
View directory record Official record
Conditions
Acute Kidney Injury, Coronary Artery Disease, Percutaneous Coronary Intervention
Interventions
Standard of care Ultra Low Contrast PCI
Procedure
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 4, 2022 · Synced Oct 6, 2026, 6:06 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Association Between a Mother's Exposure to "Strep Throat" and Her Baby's Developing Heart Disease

NCT01603732
View directory record Official record
Conditions
Congenital Heart Disease in Pregnancy
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
397 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
2
States / cities
St Louis, Missouri • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 6, 2026, 6:06 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Risk Factors, Costs, and Impacts of ED Boarding

NCT07532564
View directory record Official record
Conditions
Stroke (CVA) or TIA, Diabetes, Asthma (Diagnosis), COPD (Chronic Obstructive Pulmonary Disease), Sepsis, Hypertension, Heart Failure, Pneumonia, Urinary Tract Infection (Diagnosis), Chest Pain, Psychiatric Disorder, Sickle Cell Disease (SCD)
Interventions
Not listed
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
30,486 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 6, 2026, 6:06 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

NCT04278404
View directory record Official record
Conditions
Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Hemophilia, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome
Interventions
The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Duke University
Other
Eligibility
0 Years to 20 Years
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
49
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 40 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 6, 2026, 6:06 AM EDT
Completed No phase listed Observational

Ultrasound Markers of Organ Congestion in Severe Acute Kidney Injury

NCT04095143
View directory record Official record
Conditions
Acute Kidney Injury, Fluid Overload, Ultrasonography
Interventions
Portal vein flow, Intra-renal flow, Hepatic vein flow, Pulmonary B-lines, Dimensions of the inferior vena cava, Left ventricular function, Right ventricular function
Diagnostic Test
Lead sponsor
Centre hospitalier de l'Université de Montréal (CHUM)
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 14, 2022 · Synced Oct 6, 2026, 6:06 AM EDT
Completed Phase 2 Interventional

Effect of KW-3902IV in Combination With IV Furosemide on Renal Function in Subjects With CHF and Renal Impairment

NCT00159614
View directory record Official record
Conditions
Heart Failure, Congestive, Renal Insufficiency
Interventions
KW-3902IV
Drug
Lead sponsor
NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
6
States / cities
San Diego, California • Baltimore, Maryland • Ayer, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2008 · Synced Oct 6, 2026, 6:06 AM EDT
Completed Phase 1 Interventional

Study to Evaluate TRV120027 on Renal Pharmacodynamics in Patients With Heart Failure and Renal Dysfunction

NCT01444872
View directory record Official record
Conditions
Heart Failure, Kidney Disease
Interventions
TRV120027, Normal Saline
Drug
Lead sponsor
Trevena Inc.
Industry
Eligibility
18 Years to 74 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
4
States / cities
Orlando, Florida • Minneapolis, Minnesota • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2012 · Synced Oct 6, 2026, 6:06 AM EDT
Active, not recruiting Not applicable Interventional

Guideline-directed Management and Therapy (GDMT) for the Prevention of Postpartum Cardiac Dysfunction in Preeclamptic African American Women

NCT05534932
View directory record Official record
Conditions
Preeclampsia Postpartum
Interventions
Remote Patient Monitoring
Device
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 6, 2026, 6:06 AM EDT
Completed Phase 3 Interventional

Estrogen Treatment (Oral vs. Patches) in Turner Syndrome

NCT00140998
View directory record Official record
Conditions
Turner Syndrome, Hypogonadism, Premature Ovarian Failure
Interventions
17 beta estradiol
Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
10 Years to 16 Years · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 30, 2017 · Synced Oct 6, 2026, 6:06 AM EDT
Completed Phase 2 Interventional

Study of APX-115 in Contrast Induced Acute Kidney Injury in Subjects Undergoing PCI

NCT05758896
View directory record Official record
Conditions
Contrast Induced Acute Kidney Injury
Interventions
Isuzinaxib (APX-115), Placebo
Drug
Lead sponsor
Aptabio Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 6, 2026, 6:06 AM EDT
Completed No phase listed Observational

Verification of Risk Assignment for Whole Chromosome Using SNP-based NIPT in Vanishing Twin Pregnancies

NCT05004337
View directory record Official record
Conditions
Vanishing Twin, Trisomy 21, Trisomy 13, Trisomy 18
Interventions
Not listed
Lead sponsor
Natera, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
21
States / cities
Los Angeles, California • Palo Alto, California • Aurora, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 6, 2026, 6:06 AM EDT
Terminated Not applicable Interventional Results available

Carvedilol and Micro T-Wave Alternans in Hypertensives With Chronic Kidney Disease

NCT00638222
View directory record Official record
Conditions
Vascular Disease, Kidney Disease
Interventions
Carvedilol and Placebo
Other
Lead sponsor
University of Toledo Health Science Campus
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
Toledo, Ohio • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Nov 13, 2014 · Synced Oct 6, 2026, 6:06 AM EDT
Completed Phase 4 Interventional Results available

Impact of Chronic Kidney Disease on the Effects of Ticagrelor in Patients With Diabetes and Coronary Artery Disease

NCT02539160
View directory record Official record
Conditions
Coronary Artery Disease, Diabetes Mellitus
Interventions
ticagrelor
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 28, 2022 · Synced Oct 6, 2026, 6:06 AM EDT
Completed No phase listed Observational

Investigation in Pregnancy Associate Cardiomyopathy

NCT01085955
View directory record Official record
Conditions
Cardiomyopathy, Pregnancy
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
16 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
28
States / cities
Los Angeles, California • Miami, Florida • Augusta, Georgia + 23 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2016 · Synced Oct 6, 2026, 6:06 AM EDT